Inbrain Pharma

What Inbrain Pharma does

InBrain Pharma is a clinical-stage biopharmaceutical company developing A-Dopamine, a novel intracerebroventricular (ICV) infusion therapy for advanced Parkinson's disease patients who are refractory to conventional oral L-dopa treatment. Founded in 2018 as a spin-off of the University of Lille and headquartered in Loos (Lille Métropole), France, the company is built on academic and clinical research from the Lille Neuroscience & Cognition Research Center (LilNCog – INSERM CHU Lille-ULille) and CHU de Lille, where the underlying A-Dopamine technology and two patents were originated by co-founders Prof. David Devos and Prof. Caroline Moreau-Devos.

The company's core technology combines an anaerobic dopamine formulation (A-Dopamine) with circadian-controlled delivery via the Prometra II programmable implantable pump (manufactured by Infusyn Therapeutics), enabling continuous ICV infusion that bypasses blood-brain barrier limitations associated with oral therapies. The lead asset A-Dopamine is in Phase III development following completion of the DIVE-I monocentric clinical trial (2020-2025) conducted at CHU de Lille's neurology department. The pipeline additionally includes two undisclosed preclinical candidates, IBP-001 and IBP-002. Manufacturing scale-up for clinical and commercial supply is being executed through a CDMO partnership with IDD-Xpert for GMP-compliant anaerobic dopamine production.

InBrain Pharma is pre-revenue and operates an enterprise field-sales model intended for commercialization through hospital and specialty pharmacy channels upon EMA approval. The company is financed primarily by French public and regional investors, including Bpifrance, Finovam Gestion, Nord France Amorçage, the University of Lille Foundation, and the patient advocacy group France Parkinson. In May 2025, the company secured a €1.8M grant from France's "Première Usine" (First Factory) initiative under the France 2030 program to support the PERCEPAR project and industrialization of anaerobic dopamine production.

Name

Inbrain Pharma

Legal name

InBrainPharma SAS

Website

https://inbrainpharma.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

InBrain Pharma is a clinical-stage French biotechnology company developing A-Dopamine, an intracerebroventricular infusion therapy for advanced Parkinson's disease patients refractory to conventional oral L-dopa treatment, currently advancing through Phase III clinical trials.

Ownership category

akta.pro rank

Product category

Neurological Therapeutics

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC)

Keywords

• Neurological therapeutics
• Parkinson's disease treatment
• Central nervous system drugs
• Intracerebroventricular therapy
• Specialty pharmaceuticals

Headquarters

HQ city

Loos

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. A-Dopamine Therapy Commercialization: InBrain Pharma is a pre-revenue clinical-stage biopharmaceutical company. The primary revenue stream will be generated through commercialization of the A-Dopamine therapy following successful clinical trials and regulatory approval (EMA). The company is currently in Phase III development with pipeline candidates IBP-001 and IBP-002, along with A-Dopamine in Phase III.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

InBrain Pharma develops and manufactures A-Dopamine, a sterile, soluble-dispersible dopamine formulation administered via continuous intracerebroventricular (ICV) infusion through an implanted pump for the treatment of advanced Parkinson's disease. The therapy is designed to mimic the brain's natural circadian release of dopamine and is being advanced through Phase III clinical trials, with additional undisclosed preclinical candidates (IBP-001, IBP-002) targeting central nervous system indications.

Product overview

InBrain Pharma is a biotechnology company developing a pipeline of novel neurological therapies for Parkinson's disease. Its lead product is A-Dopamine, an innovative intracerebroventricular infusion therapy for advanced Parkinson's disease patients who are refractory to conventional L-dopa treatments, currently in Phase III. The pipeline also includes two undisclosed preclinical candidates (IBP-001 and IBP-002). The company leverages partnerships with device manufacturers (Prometra II pump by Infusyn Therapeutics) and CDMO partners (IDD-Xpert) for manufacturing and scale-up.

Differentiator

Problem solved

Functional benefit

Products and services

• A-Dopamine A sterile, soluble-dispersible dopamine formulation administered via continuous intracerebroventricular (ICV) infusion through an implanted pump, designed to mimic the brain's natural circadian dopamine release for the treatment of advanced Parkinson's disease. Currently in Phase III clinical development.

Quantifiable outcome

• DIVE-I clinical trial completed 2020-2025 with Prometra II pump for A-dopamine intracerebroventricular infusion

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• IDD-XpertcoreStrategic or Co-development Partner · 12 May 2025IDD-Xpert (International Drug Development-Xpert), based in Évreux (France), is a CDMO specializing in supporting pharmaceutical product lifecycles including preformulation, formulation, analytical development, clinical batch manufacturing, and process scale-up. IDD-Xpert will support InBrain Pharma's efforts in setting and scaling up a GMP compliant production line for A-dopamine under sterile and very strict anaerobic conditions for clinical and commercial needs.
• Infusyn Therapeutics, LLCcoreTechnology or IntegrationInfusyn Therapeutics, based in Hackettstown, NJ (USA), manufactures and markets the Prometra II pump - the most sophisticated and precise implantable, fully-programmable drug delivery pump. InBrain Pharma utilized the Prometra II pump for intracerebroventricular infusion of A-dopamine in the DIVE I clinical trial (2020-2025). Infusyn is developing Prometra with partners in oncology, CNS, and cardio-pulmonary indications.
• University of LillecoreStrategic or Co-development PartnerInBrain Pharma is a spin-off of the University of Lille, born out of academic and scientific excellence. The company works closely with the Lille Neuroscience & Cognition Research Center (LilNCog – INSERM CHU Lille- ULille) which provides high-level scientific expertise, cutting-edge research infrastructure, and an academic ecosystem for brain health innovation.
• CHU de LillecoreStrategic or Co-development PartnerLille University Hospital (CHU de Lille) partnered with InBrain Pharma on the DIVE-I clinical trial. CHU de Lille handled regulatory procedures, daily operational oversight including monitoring and data management, A-dopamine drug development and manufacturing, and statistical analyses. The hospital is co-owner of the two patents underlying the DIVE technology. Prof. David Devos and Prof. Caroline Moreau-Devos initiated the A-dopamine project at CHU de Lille.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Zambon: Italian specialty pharma with a CNS and rare-disease franchise, including Parkinson's products. Comparable as a European mid-sized specialty pharma focused on CNS therapeutics.
• Lundbeck: Danish specialty pharma with a leading neurology/CNS franchise including Parkinson's products. Comparable as an established mid-cap neurology commercializer that could be a natural acquirer or commercial partner.
• AbbVie: Markets DUOPA/Duodopa (levodopa-carbidopa intestinal gel), the closest approved therapy for advanced Parkinson's with motor fluctuations, and has acquired Cerevel to deepen its CNS/neurology pipeline. Directly comparable as it competes for the same advanced-PD refractory patient population via continuous drug delivery.
• UCB: Belgian specialty biopharma with strong neurology and rare-disease franchises. Comparable as a European mid-cap with neurology commercialization infrastructure and active interest in CNS innovation.

Emerging players

• Sage Therapeutics: CNS-focused clinical-stage biopharma developing novel neurology and psychiatry therapeutics, now partnered with Biogen. Comparable as a clinical-stage CNS specialist pursuing differentiated mechanisms in under-served neurological indications.

Direct peers

• Britannia Pharmaceuticals: Specializes in Parkinson's disease therapies including apomorphine infusion products (APO-go). Comparable as a Parkinson's-focused specialty company delivering continuous dopaminergic therapies via infusion pumps.
• Bial – Portela & Cª: Portuguese pharmaceutical company with a CNS franchise including Parkinson's treatments (e.g., opicapone, safinamide). Comparable as a specialty neurology-focused mid-cap with marketed advanced-Parkinson assets.
• Cerevel Therapeutics (acquired by AbbVie): Developed CNS therapies including Parkinson-focused assets before AbbVie acquisition. Highly comparable as a clinical-stage neuroscience company pursuing differentiated mechanisms in movement disorders.
• Mitsubishi Tanabe Pharma (via NeuroDerm acquisition): Acquired NeuroDerm to gain ND0612, a continuous subcutaneous levodopa/carbidopa infusion for advanced Parkinson's disease. Direct competitor in the continuous-dopaminergic-delivery space targeting the same refractory-PD indication.

Others

• Infusyn Therapeutics: Manufacturer of the Prometra II implantable drug-delivery pump that InBrain Pharma depends on for A-Dopamine delivery. Highly relevant as both a critical partner and an enabler whose strategic decisions directly shape InBrain Pharma's commercial pathway.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/in-brain-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inbrain Pharma